Lipid Emulsions & Infant IV Nutrition: A Systematic Review
- A review of multiple studies suggests that using fish oil lipid emulsions in infants could perhaps reduce cholestasis, a liver condition, particularly in those with parenteral nutrition-associated liver...
- The review, encompassing nine randomized studies with a total of 273 participants, categorized lipid emulsions (LE) into three groups: fish oil-containing LE, conventional soybean oil LE, and choice...
- Researchers defined PNALD/cholestasis as conjugated bilirubin levels of 2 mg/dL or greater.
Fish oil lipid emulsions (LE) may offer a lifeline for infants battling cholestasis, a serious liver condition often linked to parenteral nutrition-associated liver disease (PNALD). A recent systematic review of nine studies, encompassing 273 participants, suggests these specialized lipid emulsions, particularly those containing fish oil, could substantially reduce cholestasis in affected infants. While the results are encouraging, the evidence is based on small studies. Comparisons were made between fish oil, soybean oil, and choice LE. Researchers observed that fish oil-LEs were associated with a reduction in cholestasis compared to soybean oil-LEs. The review also found no significant differences in death or sepsis rates. For more insights, News Directory 3 provides the latest updates on medical advancements. Discover what’s next for these crucial lipid emulsions in infant nutrition as the field of study evolves.
Fish Oil Lipid Emulsions May Aid Infant Cholestasis
Updated June 4, 2025
A review of multiple studies suggests that using fish oil lipid emulsions in infants could perhaps reduce cholestasis, a liver condition, particularly in those with parenteral nutrition-associated liver disease (PNALD). However,the evidence supporting this finding is considered low quality.
The review, encompassing nine randomized studies with a total of 273 participants, categorized lipid emulsions (LE) into three groups: fish oil-containing LE, conventional soybean oil LE, and choice LE. Comparisons were made between these groups across various infant conditions, including surgical cases and those with PNALD/cholestasis.
Researchers defined PNALD/cholestasis as conjugated bilirubin levels of 2 mg/dL or greater. Resolution was defined as levels dropping below 2 mg/dL. Definitions and detection times for PNALD varied across the included studies.
In infants with existing cholestasis, the use of fish oil-LEs showed a significant association with reduced cholestasis compared to soybean oil-LEs. The review indicated that three infants would need to be treated with fish oil-LEs to achieve one additional beneficial outcome. However, this conclusion stems from a limited number of participants in two small studies with differing methodologies, increasing uncertainty.
One study noted better weight gain in infants with cholestasis receiving pure fish oil LE compared to a 10% soybean oil LE. No significant differences in growth parameters were observed in surgical populations.
Secondary outcomes revealed mixed results. One study reported lower conjugated bilirubin levels but higher gamma glutamyl transferase levels with a specific multisource LE compared to soybean oil LE. Another study, terminated early, showed higher rates of increase in certain liver enzymes in the soybean oil LE group compared to pure fish oil LE.
The review found no evidence of differences in death, sepsis, or other liver enzyme levels in infants with surgical conditions or cholestasis. Neurodevelopmental outcomes and head growth velocity also showed no significant differences between fish oil and soybean oil LE groups.
What’s next
Further research with larger,multi-center studies is needed to confirm these findings and establish clear guidelines for the use of fish oil lipid emulsions in infant nutrition,especially concerning the management of PNALD and cholestasis.